Apogee Therapeutics, Inc.
APGE NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 10, 2026
ET
EPS Est.
-1.07
EPS Actual
-1.14
Revenue Est.
$10M
Revenue Actual
--
Next Earnings Report Date unconfirmed
Date
Nov 9, 2026 · Mon
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
-1.14
Revenue Est.
$10M
Company Overview
Apogee Therapeutics, Inc. (ticker APGE) is listed on NASDAQ with a market cap of about $8.34B. Its next earnings report (FY2026 Q3) is expected on Nov 9, 2026 (ET), Pre-market (date pending company confirmation), with consensus EPS of -1.14. In the last 13 reported quarters, EPS beat consensus estimates 7 times.
Actual EPS TrendRecently15Term · Dec 31, 2022 → Aug 10, 2026
Dec 31, 2022Range: -3.78 ~ -0.28Aug 10, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 10, 2026 | -- | -1.07 | -1.14 | $10M | -- |
| May 11, 2026 | -- | -1.07 | -1.06 | -- | -- |
| Mar 2, 2026 | -- | -1.05 | -1.03 | -- | -- |
| Nov 10, 2025 | -- | -1.12 | -1.11 | -- | -- |
| Aug 11, 2025 | -- | -1.03 | -1.13 | -- | -- |
| May 12, 2025 | -- | -1.19 | Above forecast↑-0.95 | -- | -- |
| Mar 3, 2025 | -- | -0.94 | Below forecast↓-1.19 | -- | -- |
| Nov 12, 2024 | -- | -0.88 | -0.86 | -- | -- |
| Aug 12, 2024 | -- | -0.64 | -0.60 | -- | -- |
| May 13, 2024 | -- | -0.60 | -0.64 | -- | -- |
| Mar 5, 2024 | -- | -0.49 | Above forecast↑-0.32 | -- | -- |
| Nov 13, 2023 | -- | -0.38 | Below forecast↓-0.51 | -- | -- |
| Aug 28, 2023 | -- | -1.70 | Below forecast↓-3.78 | -- | -- |
| May 31, 2023 | -- | -- | -2.51 | -- | -- |
| Dec 31, 2022 | -- | -- | -0.28 | -- | -- |
Original Filings (SEC)
8-K2026-08-11 ↗
10-Q2026-08-10 ↗
8-K2026-08-10 ↗
8-K2026-06-22 ↗
8-K2026-06-22 ↗
8-K2026-06-12 ↗
8-K2026-05-27 ↗
8-K2026-05-27 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
